China’s NMPA accepts BeiGene’s sBLA for hepatocellular carcinoma treatment

BeiGene is seeking marketing approval for tislelizumab to treat hepatocellular carcinoma. Credit: Atlas of Pulmonary Pathology/ Flickr.